Massachusetts

Website errors raise calls for Medicare to Be flexible with seniors’ enrollment

Beneficiaries are going to be able to change plans next year because of misinformation through the website for Medicare enrollment although officials provided few details. Source link

Read more
What will it take to improve recruitment for clinical trials?

Whether clinical trial travel requires a short rideshare trip or a flight halfway across the world, the key to keeping participants enrolled and engaged is to make it as convenient...

Read more
Massachusetts Passes Bill to Ban All Flavored Vaping Products

Bill would also put 75 percent excise tax on vaping products Source link

Read more
Angion’s kidney therapy advances

The 28-patient study showed that Angion’s drug improved kidney function, based on patients’ estimated glomerular filtration rate (eGFR), a key renal function metric. Source link

Read more
Why Google is buying Fitbit

We spoke to investors and analysts to figure out why Google is buying Fitbit, a company that hasn’t made much of a dent in the healthcare world. Source link

Read more
Amgen to stop selling Repatha at higher list price, offer low-priced option exclusively

The biotech company had kept the drug available at the higher list price in order to give payers and pharmacy benefit managers time to adjust contracts and minimize supply chain...

Read more
Download the HLTH app to maximize your networking game

In its second year, HLTH is offering a smorgasbord of programs designed to facilitate networking at its conference at the MGM Grand in Las Vegas October 27-30. Source link

Read more
Get ready for the second annual HLTH conference

MedCity’s patient engagement conference ENGAGE will be part of the HLTH conference for the first time this year. ENGAGE at HLTH on October 28 will feature innovators from across the health ecosystem drawing...

Read more
UCB psoriasis drug beats J&J’s second top-selling product in Phase III study

Results of the BE VIVID study showed that UCB’s bimekizumab showed a statistically significant improvement in skin clearance compared with J&J’s Stelara and placebo. Source link

Read more
Whistleblower alleges Medicare fraud at iconic Seattle-based health plan

The Justice Department has thus far declined to take over the case, which alleges wrongdoing by Seattle-based nonprofit health plan, Group Health, but said in a June 21 court filing...

Read more
A look at the different ways in which HIPAA is enforced

Although historically they have been infrequent, the pace of settlements from attorneys general has picked up over recent years. Source link

Read more
Emmaus withdraws European application for sickle cell drug that got US approval

The company said it would withdraw the application for Xyndari after the EMA’s Committee for Medicinal Products for Human Use followed a negative opinion from May. The FDA approved the...

Read more
Comprehensive managed vision care is more than mere “medical management”

As U.S. healthcare continues to evolve, understanding true utilization management is critical now more than ever and managed vision care serves as an opportunity for an integrated, cost-effective, non-invasive look at...

Read more
Your guide to networking events at HLTH

Here’s a roundup of networking opportunities at the healthcare innovation conference in Las Vegas October 27-30 at the MGM Grand. Source link

Read more
EEE Virus In Massachusetts Update: Why Bay State Is Being Targeted By Mosquitoes

Experts believe that a certain feature of the U.S. state makes it susceptible for mosquitoes carrying the disease to thrive. Source link

Read more
The business case for integrating claims and clinical data 

By partnering with a smart, secure, and collaborative health data network, providers and health plans can access integrated claims and clinical data and more effectively transition to value-based care. Source link

Read more
Sanofi’s billion-dollar multiple sclerosis drug faces competitive threat from Novartis, J&J agents

On Friday, Novartis presented data at ECTRIMS showing that Arzerra had superior efficacy to Sanofi’s Aubagio. Johnson & Johnson’s Janssen division had presented data for its drug, ponesimod, two days...

Read more
You are where you work

Moving away from the sick care toward primary care is not only a more efficient way to address social determinants of health in the workplace, but a more budget-friendly one...

Read more
Despite repeated calls for unity, democrats throw debate punches on health plans

Each candidate staked out a place on the health policy continuum but the biggest divide was between former Vice President Joe Biden — whose health care proposal includes a government-run...

Read more
FDA expert panel gives thumbs-up to Aimmune’s peanut allergy drug

The FDA’s Allergenic Products Advisory Committee voted 7-2 in favor of supporting the efficacy profile of Palforzia, or AR101. Some committee members expressed concerns about a lack of diversity in...

Read more